Suven Pharmaceuticals Ltd. (IN:COHANCE)
:COHANCE
Want to see IN:COHANCE full AI Analyst Report?
Total Valuation
Suven Pharmaceuticals Ltd. has a market cap or net worth of ₹160.83B. The enterprise value is ₹163.53B.
Market Cap₹160.83B
Enterprise Value₹163.53B
Share Statistics
Suven Pharmaceuticals Ltd. has 382,567,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding382,567,140
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Suven Pharmaceuticals Ltd.’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 3.32%.
Return on Equity (ROE)0.05
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)3.32%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee19.02M
Profits Per Employee1.50M
Employee Count1,193
Asset Turnover0.40
Inventory Turnover2.41
Valuation Ratios
The current PE Ratio of Suven Pharmaceuticals Ltd. is 64.3. Suven Pharmaceuticals Ltd.’s PEG ratio is -1.16.
PE Ratio64.3
PS Ratio5.08
PB Ratio2.95
Price to Fair Value2.95
Price to FCF85.28
Price to Operating Cash Flow61.44
PEG Ratio-1.16
Income Statement
In the last 12 months, Suven Pharmaceuticals Ltd. had revenue of 22.69B and earned 1.79B in profits. Earnings per share was 4.69.
Revenue22.69B
Gross Profit9.11B
Operating Income2.40B
Pretax Income2.07B
Net Income1.79B
EBITDA4.27B
Earnings Per Share (EPS)4.69
Cash Flow
In the last 12 months, operating cash flow was 2.61B and capital expenditures -897.10M, giving a free cash flow of 1.71B billion.
Operating Cash Flow2.61B
Free Cash Flow1.71B
Free Cash Flow per Share4.48
Dividends & Yields
Suven Pharmaceuticals Ltd. pays an annual dividend of ₹5, resulting in a dividend yield of ―
Dividend Per Share₹5
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.04
52-Week Price Change-61.19%
50-Day Moving Average370.10
200-Day Moving Average594.12
Relative Strength Index (RSI)49.60
Average Volume (3m)116.47K
Important Dates
Suven Pharmaceuticals Ltd. upcoming earnings date is Aug 7, 2026, TBA (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 7, 2026
Ex-Dividend Date―
Financial Position
Suven Pharmaceuticals Ltd. as a current ratio of 2.78, with Debt / Equity ratio of 10.24%
Current Ratio2.78
Quick Ratio1.91
Debt to Market Cap0.02
Net Debt to EBITDA0.80
Interest Coverage Ratio6.44
Taxes
In the past 12 months, Suven Pharmaceuticals Ltd. has paid 569.20M in taxes.
Income Tax569.20M
Effective Tax Rate0.27
Enterprise Valuation
Suven Pharmaceuticals Ltd. EV to EBITDA ratio is 27.78, with an EV/FCF ratio of 87.80.
EV to Sales5.23
EV to EBITDA27.78
EV to Free Cash Flow87.80
EV to Operating Cash Flow33.41
Balance Sheet
Suven Pharmaceuticals Ltd. has ₹4.03B in cash and marketable securities with ₹4.51B in debt, giving a net cash position of -₹479.20M billion.
Cash & Marketable Securities₹4.03B
Total Debt₹4.51B
Net Cash-₹479.20M
Net Cash Per Share-₹1.25
Tangible Book Value Per Share₹69.36
Margins
Gross margin is 62.85%, with operating margin of 10.56%, and net profit margin of 7.90%.
Gross Margin62.85%
Operating Margin10.56%
Pretax Margin9.13%
Net Profit Margin7.90%
EBITDA Margin18.82%
EBIT Margin10.56%
Analyst Forecast
The average price target for Suven Pharmaceuticals Ltd. is ₹300.00, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target₹300.00
Price Target Upside-66.33% Downside
Analyst ConsensusModerate Sell
Analyst Count1
Revenue Growth Forecast89.43%
EPS Growth Forecast-55.47%